Literature DB >> 7871117

Psychopathology of Schizophrenia: initial validation of a 5-factor model.

J P Lindenmayer1, R Bernstein-Hyman, S Grochowski, N Bark.   

Abstract

Schizophrenic psychopathology is heterogeneous and multidimensional. One of the more fruitful strategies to investigate more homogenous domains of psychopathology has been the positive-negative syndrome approach. However, this approach is unable to address a number of important issues. Most schizophrenics present a mixed syndrome; the criteria for what constitutes a positive and negative syndrome are variable; distinguishing primary from secondary negative symptoms can be difficult. In order to address some of these problems, we propose the introduction of a 5-syndrome model based on a reanalysis of factor-analytic procedures used on 240 schizophrenics assessed with the Positive and Negative Syndrome Scale: A negative, positive, excitement, cognitive and depression/anxiety factor. This 5-factor solution is supported by 4 independent and comparable factor analyses. Data on internal consistency of the 5 factors and on initial validation using demographic and clinical variables are presented.

Entities:  

Mesh:

Year:  1995        PMID: 7871117     DOI: 10.1159/000284896

Source DB:  PubMed          Journal:  Psychopathology        ISSN: 0254-4962            Impact factor:   1.944


  23 in total

Review 1.  Recent advances in the genetics of schizophrenia.

Authors:  D M Waterwort; A S Bassett; L M Brzustowicz
Journal:  Cell Mol Life Sci       Date:  2002-02       Impact factor: 9.261

2.  Investigation of anatomical thalamo-cortical connectivity and FMRI activation in schizophrenia.

Authors:  Stefano Marenco; Jason L Stein; Antonina A Savostyanova; Fabio Sambataro; Hao-Yang Tan; Aaron L Goldman; Beth A Verchinski; Alan S Barnett; Dwight Dickinson; José A Apud; Joseph H Callicott; Andreas Meyer-Lindenberg; Daniel R Weinberger
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 3.  Brexpiprazole: so far so good.

Authors:  Saibal Das; Preeti Barnwal; Blessed Winston A; Somnath Mondal; Indranil Saha
Journal:  Ther Adv Psychopharmacol       Date:  2016-02

4.  Comparison of visual perceptual organization in schizophrenia and body dysmorphic disorder.

Authors:  Steven M Silverstein; Corinna M Elliott; Jamie D Feusner; Brian P Keane; Deepthi Mikkilineni; Natasha Hansen; Andrea Hartmann; Sabine Wilhelm
Journal:  Psychiatry Res       Date:  2015-06-27       Impact factor: 3.222

5.  Catechol-O-methyl transferase and expression of schizophrenia in 73 adults with 22q11 deletion syndrome.

Authors:  Anne S Bassett; Oana Caluseriu; Rosanna Weksberg; Donald A Young; Eva W C Chow
Journal:  Biol Psychiatry       Date:  2007-01-09       Impact factor: 13.382

Review 6.  Understanding Antipsychotic Drug Treatment Effects: A Novel Method to Reduce Pseudospecificity of the Positive and Negative Syndrome Scale (PANSS) Factors.

Authors:  Seth C Hopkins; Ajay Ogirala; Antony Loebel; Kenneth S Koblan
Journal:  Innov Clin Neurosci       Date:  2017-12-01

7.  Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo-controlled study in healthy volunteers.

Authors:  Tanja Veselinović; Holger Schorn; Ingo Vernaleken; Katharina Schiffl; Christoph Hiemke; Gerald Zernig; Ruben Gur; Gerhard Gründer
Journal:  Psychopharmacology (Berl)       Date:  2011-06-04       Impact factor: 4.530

8.  Physio-somatic symptoms in schizophrenia: association with depression, anxiety, neurocognitive deficits and the tryptophan catabolite pathway.

Authors:  Buranee Kanchanatawan; Sunee Sirivichayakul; Supaksorn Thika; Kiat Ruxrungtham; André F Carvalho; Michel Geffard; George Anderson; Cristiano Noto; Rada Ivanova; Michael Maes
Journal:  Metab Brain Dis       Date:  2017-03-03       Impact factor: 3.584

9.  The schizophrenia phenotype in 22q11 deletion syndrome.

Authors:  Anne S Bassett; Eva W C Chow; Philip AbdelMalik; Mirona Gheorghiu; Janice Husted; Rosanna Weksberg
Journal:  Am J Psychiatry       Date:  2003-09       Impact factor: 18.112

10.  Fluvoxamine dose-dependent interaction with haloperidol and the effects on negative symptoms in schizophrenia.

Authors:  Norio Yasui-Furukori; Tsuyoshi Kondo; Kazuo Mihara; Yoshimasa Inoue; Sunao Kaneko
Journal:  Psychopharmacology (Berl)       Date:  2003-09-04       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.